Go to deals
Saúde

St. Claraspital AG has been acquired by University Hospital Basel

University Hospital Basel (USB) has acquired St. Claraspital AG, expanding its network of specialized care and integrated services. With St. Claraspital’s strong community presence, expertise in acute and rehabilitation medicine and established outpatient clinics, this merger enhances USB’s ability to provide seamless, patient-centered treatment across the continuum of care.

St. Claraspital is a leading, systemically relevant hospital in Northwestern Switzerland, delivering high-quality care ranging from primary care services to highly complex treatments, with a particular focus on tumor and abdominal care. A round-the-clock emergency department and intensive care unit, supported by specialized, adjacent and diagnostic disciplines, ensure seamless and integrated patient care.

USB is one of Switzerland’s leading university hospitals and the largest healthcare center in Northwestern Switzerland. Founded in 1460 as part of the University of Basel’s Faculty of Medicine, USB now employs around 8,000 staff members, operates more than 700 beds and treats approximately 40,000 inpatients each year. Comprising 12 medical centers, USB offers comprehensive care across all medical specialties and collaborates closely with the University of Basel and leading life sciences companies.

Oaklins’ team in Switzerland acted as the lead advisor to the seller throughout the sales process, including preparation and approach, due diligence and parallel negotiations with potential buyers.

Entidades
“I experienced the Oaklins Swiss team as a highly professional partner with outstanding transaction expertise. Throughout the engagement, collaboration took place at the senior level — built on trust, focus and mutual respect. The experienced team executed the ambitious timeline with great commitment, managing the process both efficiently and in a structured manner. This enabled us to select the very best new owner for St. Claraspital from several attractive options — an outcome that met the seller’s expectations in every respect.”

Raymond Cron

Chairman of the Board, St. Claraspital AG

Falar com a equipa da transação

David Zürrer

Partner
Basileia, Suíça
Oaklins Switzerland

Jens Rutten

Partner
Zurique, Suíça
Oaklins Switzerland

Florian Mattern

Senior Associate
Zurique, Suíça
Oaklins Switzerland

Moritz Henniger

Analyst
Basileia, Suíça
Oaklins Switzerland

Transações relacionadas

MEDIK Hospital Design Group has been acquired by STERIS
Contrução & Serviços de Engenharia | Saúde

MEDIK Hospital Design Group has been acquired by STERIS

The private shareholders of MEDIK Hospital Design Group have sold their shares to STERIS plc. Together, MEDIK and STERIS will expand their offerings for hospitals and ambulatory surgery centers worldwide. MEDIK’s solutions ideally complement STERIS’ existing portfolio, enabling the combined group to strengthen its position as a leading provider of turnkey room solutions in surgical and IPT environments. The MEDIK management team will actively support the next phase of growth.

Saber mais
bioXXmed AG has sold Rancoderm GmbH to Rose Investment- und Beteiligungs AG
Saúde

bioXXmed AG has sold Rancoderm GmbH to Rose Investment- und Beteiligungs AG

Rancoderm GmbH has been acquired by Rose Investment- und Beteiligungs AG to secure the funding required for the final development and market approval of its medical device DermaPro. The acquisition will enable Rancoderm to bring DermaPro to market readiness and launch it as a certified medical product for broad distribution.

Saber mais
Banook, backed by Motion Equity, has acquired Fluidda
Saúde | TMT

Banook, backed by Motion Equity, has acquired Fluidda

Banook Group has acquired Fluidda NV, marking a strategic expansion into advanced in-silico trials and respiratory disease modeling. Combining Banook’s expertise in cardiac safety and clinical data services with Fluidda’s AI-driven respiratory analytics creates a powerful, integrated platform. This deal strengthens Banook’s position in the contract research organization (CRO) sector, offering pharmaceutical clients broader, technology-enabled solutions to drive drug development and reduce costs.

Saber mais